Baird’s Celgene Corp CELG Stock Holding History

Baird’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$23M	Sell	199,139 -17,275	-8%	-$2.06M	0.23%	130
2014 Q4	$24.2M	Buy	216,414 +7,248	+3%	+$764K	0.26%	121
2014 Q3	$19.8M	Sell	209,166 -42,130	-17%	-$3.8M	0.28%	106
2014 Q2	$21.6M	Sell	251,296 -8,950	-3%	-$681K	0.3%	97
2014 Q1	$18.2M	Buy	260,246 +22,754	+10%	+$1.8M	0.26%	108
2013 Q4	$20.1M	Buy	237,492 +140	+0.1%	+$11.1K	0.35%	70
2013 Q3	$18.3M	Sell	237,352 -65,620	-22%	-$4.6M	0.34%	67
2013 Q2	$17.7M	Buy	+302,972	New	+$18.2M	0.35%	63

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Baird's CELG Position: Q1 2015 in Review

Baird reduced its Celgene Corp (CELG) stake by 8% in Q1 2015, selling an estimated $2.06M and leaving 199,139 shares worth $23M. The position accounts for 0.23% of the portfolio, ranked #130.

Baird first reported a position in CELG in Q2 2013 and has held it in 8 quarters since. The position peaked at $24.2M in Q4 2014. 1,193 funds tracked by Wall St. Rank hold CELG as of Q1 2015.

Baird held 199,139 shares of Celgene Corp worth $23M as of Q1 2015.
Baird sold 17,275 Celgene Corp shares in Q1 2015, an estimated $2.06M.
Celgene Corp made up 0.23% of Baird's portfolio in Q1 2015, its #130 holding.
Baird first reported a position in Celgene Corp in Q2 2013 and has held it in 8 quarters since.
Baird's Celgene Corp position peaked at $24.2M in Q4 2014.
1,193 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.